NCT03399110CompletedPhase 3
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
XELOX for 4 Months Versus 6 Months as Adjuvant Chemotherapy in Gastric Cancer After D2 Resection (LOMAC)
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
Our study aims to compare 4 months versus 6 months of adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in patients with gastric cancer. Hypothesis: We hypothesize that a 4-month regimen of capecitabine plus oxaliplatin is noninferior to a 6-month regimen with respect to DFS and is associated with lower treatment-related toxicity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1024 (actual)
- First submitted
- 8 Jan 2018
- Start date
- 14 Jan 2018
- Primary completion date
- 15 Aug 2026
- Lead sponsor
- Fudan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT03399110
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 1024
- From 14 Jan 2018 to the primary completion date, 15 Aug 2026
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receipt of preoperative treatment, including radiation therapy, chemotherapy, or immunotherapy.
Other illness
- Patients with stage I, IIIC, or IV gastric cancer.
- Severe cardiac, pulmonary, neurologic, hepatic, or other major organ dysfunction.
- Known or suspected drug allergies.
Other
- Pregnant or lactating women.
Who the study is looking for
- Age between 18 and 80 years.
- Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction, staged as II, IIIA, or IIIB according to the American Joint Committee on Cancer classification system, eighth edition.
- Underwent R0 gastrectomy with D2 lymphadenectomy.
- No other concurrent malignancies.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- No contraindications to chemotherapy.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| The First Affiliated Hospital of Anhui Medical University Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| The First Affiliated Hospital of University of Science and Technology of China Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Jiangsu Cancer Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| Shanghai East Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Second Affiliated Hospital (Changzheng Hospital) of Naval Medical University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Changhai Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Liaoning Cancer Hospital Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
| The First Affiliated Hospital of Wannan Medical College Coordinator of this site? Confirm its status | Wuhu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.